<DOC>
	<DOC>NCT01986140</DOC>
	<brief_summary>Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.</brief_summary>
	<brief_title>Scalp Cooling to Prevent Chemo-induced Hair Loss</brief_title>
	<detailed_description>Cooling the scalp during chemotherapy may help reduce the chances of losing hair during treatment. The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device may stop patients who are undergoing chemotherapy from losing their hair.</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>New diagnosis of breast cancer stage 12 Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent Chemotherapy must be planned for at least 4 cycles of fulldose anthracycline or taxane based chemotherapy regimen, Defined as one of the following regimens: Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2 Epirubicin 90100mg/m2 with cyclophosphamide 600mg/m2 Paclitaxel 80mg90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 23 weeks as a single agent Docetaxel 100mg/m2 as a single agent Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2 Docetaxel 75mg/m2 with carboplatin AUC of 6 and trastuzumab at standard doses Trastuzumab at standard doses is allowed in combination with taxane based chemotherapy Administration of chemotherapy on a dose dense schedule is allowed as clinically indicated. Stage 3 or 4 breast cancer or any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma) Baseline alopecia (defined CTCAE v4.0 grade &gt; 0, see appendix B for CTCAE v4.0 scale) Subjects with cold agglutinin disease or cold urticaria Subjects who are scheduled for bone marrow ablation chemotherapy Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC) Male gender</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Alopecia</keyword>
	<keyword>Scalp</keyword>
	<keyword>Cooling</keyword>
</DOC>